Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
PRNewswire - October 19, 1999
The investigators at AIDS ReSEARCH Alliance, Stephen J. Brown, M.D. and George Fareed, M.D., studied 14 patients in an open-label study using two doses of Multikine. The patients were HIV-1 infected, treated with concomitant HAART (Highly Active Anti-Retroviral Therapy), had CD4+ counts in excess of 500 and a viral load of less than 50,000 copies/ml by PCR. Multikine was self-administered subcutaneously 5 times a week for 8 weeks. The patients were followed through week 12.
Preliminary findings indicated Multikine to be both safe and well- tolerated. The key finding in this study, other than safety, was that some patients showed an increased ability to respond to several recall antigens, such as Tetanus toxoid, Candida antigen and Proteus antigen. Restoration of immune response to recall antigens suggests an improved cellular immunity and ability to resist opportunistic infections, such as candidiasis (oral thrush). HIV-infected patients generally lose their capacity to respond to recall antigens. The results of this small trial suggest that Multikine treatment may be useful in lowering the incidence and/or lessening the severity of opportunistic infections in HIV-infected patients. However, as the investigators have recommended, larger studies are needed to confirm these preliminary findings. Further details will be presented at a scientific conference and submitted for publication.
Multikine is a mixture of naturally occurring immune system regulators called cytokines. One of these cytokines, Interleukin-2, is currently being tested as an immune booster in HIV-infected patients. Multikine has been tested in over 100 patients and is currently in several phase II trials in 6 countries against head and neck cancer.
CEL-SCI Corporation is a biopharmaceutical company whose mission it is to mobilize the immune system to combat disease.
"CEL-SCI press releases are available through Company News On-Call by fax, (800) 758-5804, Ext. 445563, or at http://www.cel-sci.com on the Internet."
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1998. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
SOURCE CEL-SCI Corporation
CONTACT: Media Contact: Geert Kersten, Chief Executive Officer of CEL- SCI Corporation, 703-506-9460; or Investor Relations: Daryll Strahl, 970-377-2216, for CEL-SCI Corporation/
Web Site: /http://www.cel-sci.com/
991019
PR991036
Copyright © 1999 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .